Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.

Obeticholic acid-a new therapy in PBC and NASH

Chapman, Roger W, Lynch, Kate D · 2020 · British Medical Bulletin

Abstract

Introduction: Obeticholic acid (OCA) is a semi-synthetic hydrophobic bile acid (BA) analogue that is highly selective agonist of farnesoid X receptor (FXR), a key nuclear BA receptor, which induces expression of gut-derived hormones, in particular fibroblast growth factor 19. The resulting beneficial effects of OCA on glucose and lipid metabolism and particularly hepatic inflammation make it a candidate for the treatment of a variety of conditions including primary biliary cholangitis (PBC) and nonalcoholic steatohepatitis (NASH). Sources of data: In PBC patients who have not initially responded to ursodeoxycholic acid, OCA has been shown in double-blind controlled clinical trials to significantly reduce serum alkaline phosphatase. To date, OCA is the only therapy licensed by the FDA, EMA and endorsed by NICE as second line therapy for PBC. No medications are currently approved in Europe or the USA for the treatment of NASH. In recent clinical trials, OCA has been shown encouraging results by improving liver blood tests and reducing liver fibrosis with no worsening of NASH. Areas of agreement: OCA is the established second line therapy for PBC in those patients who fail to adequately respond to ursodeoxycholic acid. Areas of controversy: The main side effects of OCA treatment in both PBC and NASH is that of dose-dependent pruritis which can lead to treatment discontinuation in ~1–10% of patients. In addition, OCA-treated patients may also exhibit (reversible) alterations in serum lipid levels; most notably a small decrease in high density lipoprotein cholesterol. It is not yet known whether these changes carry a long-term cardiovascular risk in NASH. In addition, the relatively high cost of OCA may limit its use in cash-limited health systems. Growing Points: Additional clinical trials are in progress to ascertain the long-term effects of OCA on survival in PBC and NASH. Areas timely for developing research: New FXR agonists with a lower rate of side effects are being developed and trialed. Combination therapy with other agents may offer increased efficacy.

Overview

Integrity signals

Registry

Crossref · 10.1093/bmb/ldaa006

Cites

25 of 25 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 25 references

Cited by

See all 119

Metadata

Authors
Chapman, R. W., & Lynch, K. D.
Affiliations
  • University of Oxford (GB)
  • Royal Adelaide Hospital (AU)
Corresponding author
Chapman, Roger W
Venue
British Medical Bulletin
Published
2020-03
Volume
133
Issue
1
Pages
95-104
ISSN
  • 0007-1420 (ISSN-L)
  • 1471-8391
OpenAlex
W3015589350
Cited by
116
References
25
Citations by year
2026: 15 · 2025: 19 · 2024: 34 · 2023: 17 · 2022: 16 · 2021: 12 · 2020: 3
FWCI
7.06
Type
journal article
Language
en
Open access
closed
Locations
  • British Medical Bulletin (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
  • Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
  • Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
Keywords
obeticholic acid, farnesoid X receptor agonist, primary biliary cirrhosis, nonalcoholic steatohepatitis, bile acid analogues, ursodeoxycholic acid, FGF19, pruritus, serum alkaline phosphatase, liver fibrosis, HDL cholesterol, cardiovascular risk, drug costs, combination therapy
MeSH terms
Receptor, Farnesoid X-Activated, Chenodeoxycholic Acid, Gastrointestinal Agents, Humans, Liver Cirrhosis, Biliary, Treatment Outcome, Receptors, Cytoplasmic and Nuclear, Non-alcoholic Fatty Liver Disease

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Obeticholic acid-a new therapy in PBC and NASH. https://app.cochat.ai/papers/10.1093/bmb/ldaa006
The paper
Chapman, R. W., & Lynch, K. D. (2020). Obeticholic acid-a new therapy in PBC and NASH. British Medical Bulletin. https://doi.org/10.1093/bmb/ldaa006

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.